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Abstract
Alexandria S. Senetra
INVESTIGATION OF THE SEQUENCE-STRUCTURE-ACTIVITY RELATIONSHIP
IN PONERICIN L1 FROM NEOPONERA GOELDII
&
SYNERGISTIC INTERACTIONS OF IONIC LIQUIDS AND ANTIMICROBIALS TO
IMPROVE EFFICACY
2019-2020
Gregory A. Caputo, Ph.D.
Master of Science in Pharmaceutical Sciences

Non-traditional antimicrobials have been an area of great interest due to the
increasing prevalence of antimicrobial resistance (AMR) in bacteria. Antimicrobial
peptides (AMPs) & ionic liquids (ILs) are two examples that have been investigated as a
potential solution. Most AMPs are naturally derived & exhibit high selectivity against
bacterial targets over host cells. The venom-derived peptide, ponericin L1 from
Neoponera goeldii, was used to investigate the role of cationic residues & net charge on
peptide activity. Using both in vitro & microbiological methods, L1 peptide & derivatives
exhibited an α-helical conformation with enhanced binding to lipid vesicles containing
anionic lipids & low hemolytic activity. Net charge & identity of the cationic groups on
the peptide were shown to play a significant role in antimicrobial activity. ILs have also
been investigated in combination with antimicrobial compounds to fight AMR.
Imidazolium chloride-based ILs with differing alkyl tails & commercially available
antibiotics were used to examine the potential for synergistic effects on multiple bacteria.
Analysis of the IL data indicates that length of the alkyl chain play a crucial role in
antimicrobial activity & cytotoxicity. A synergistic effect was exhibited while showing
low cytotoxicity when tested in a mammalian cell culture model.
v
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Chapter 1
Overview of Antimicrobials
Background
History of antimicrobials. For thousands of years, infections had reached
epidemic proportions costing the lives of millions [1]. There have been many
interventions throughout time to prevent and control the spread of infection. For example,
in 1846, a Hungarian physician, Semmelweis, found that mortality from childbed fever in
women who delivered babies by midwives was lower than those delivered by physicians.
Semmelweis concluded that this issue was a result of cadaverous materials on the hands
of medical students who came from the autopsy chamber to the obstetric clinic. This led
to the implementation of hand washing in a chlorinated lime solution before having
contact with patients, dropping the mortality rate among women that were being cared for
by physicians [2]. Another groundbreaking discovery occurred in 1928, when Alexander
Fleming found the first antibiotic, penicillin [3-4]. Then, the discovery that bacteria could
be isolated, cultured and act as a bioactive molecule was identified. In 1941, the term
antibiotic was first used by Selman Waksman to describe any small molecule produced
by a microbe that prevents the growth of another microbe [5]. Multiple antibiotic classes
with different targets were discovered and soon an assembly line production of penicillin,
streptomycin, chloramphenicol, and tetracycline were the segue to the antibiotic age
(1945-1955).
Discovery, commercialization, and routine administration of antibiotics has
become one of the most important medical interventions to treat infectious diseases [6].
1

Millions of lives have been saved due to antibiotics [7]. Although, antibiotics are known
to save lives, the over-prescribing have arguably led to the epidemic of multi-drug
resistant (MDR) microbes [8]. The capability for multiple types of bacteria to rapidly
develop mechanisms of resistance to common medications threatens the prevention and
treatment for infections. Antimicrobial resistance (AMR) has become a major health
threat globally due to an increased mortality rate in people with a multi-drug resistant
bacterial infection [9].
When treating a multi-drug resistant (MDR) infection, even some of the most
potent antibiotics are unable to kill these “superbugs” [4]. With delayed development of
new antibiotics [10], there is an urgent need for novel antimicrobial strategies and/or
alternative drugs to revive the potency of traditional antibiotics, prevent mortality, and
help reduce the chances of antimicrobial resistance [11]. An example of a new
antimicrobial drug is antimicrobial peptides (AMPs). AMPs are a growing class of
naturally derived novel antibacterial molecules with unique antimicrobial mechanisms. In
various organisms such as plants, animals, and humans, AMPs contain important
components for the innate immune system, which become the first-line defense against
an infection [12-13].
History of antimicrobial peptides. In 1939, Dubos isolated tyrothricin, an
antimicrobial agent, from a spore-bearing soil Bacillus strain, which protected mice from
a pneumococci infection [14]. This led to the first discovery of an AMP named
gramicidin [15]. Although toxicity was associated with intraperitoneal application,
gramicidin was effective in treating wounds and ulcers topically [16]. Another AMP
extracted from tyrothricin, tyrocidine, was discovered in 1941, and exhibited
2

antimicrobial activity against both Gram-negative and Gram-positive bacteria [17].
Although tyrocidine was effective against bacteria, strong hemolytic activity was also
shown, making it a poor choice for a therapeutic [18]. Later that year, purothionin was
isolated from the plant Triticumaestivum and was effective against some pathogenic
bacteria, along with fungi [19]. In 1956, the first animal isolated AMP was a defensin
found in rabbit leukocytes [20]. Defensins are the largest class of mammalian AMPs and
have been found throughout evolution. They play a key role in the innate immune
response to infection, as well as being implicated in wound healing and immune
modulation [180].
As of 2016, there have been over 23,000 AMPs discovered including both natural and
synthetic [21]. Natural AMPs have been found in various sources such as bacteria,
invertebrates, vertebrates, and plants [22]. AMPs extracted from animals are mainly
found in the tissues and organs exposed to airborne pathogens to stop most infections
before symptoms develop [23], [24]. There are various types of eukaryotic cells involved
in the production of AMPs including epithelial cells in gastrointestinal and genitourinary
systems [25-26], phagocytes [27], and lymphocytes of the immune system [28-29]. Frog
skin, for example, contains over 300 different AMPs [30-31]. An example of an AMP
extracted from the ventral skin of the frog, Xenopus laevis, is called magainin [32].
Magainins are produced by the mucous glands in the skin of the frog and exhibit broadspectrum antimicrobial activity against bacteria, fungi, and protozoa [33].
Structures and characteristics of antimicrobial peptides. AMPs are normally
amphipathic, cationic peptides with a varying amino acid chain of about five to less than
50 exhibiting an overall positive charge. AMPs have shown interaction with a broad
3

spectrum of organisms, such as bacteria, including multi-drug resistant bacteria [34],
cancer [35], viruses [36], fungi [37], and even parasites [38]. They have also been shown
to rapidly kill cells in seconds after initial contact with their target [39].
Based on their secondary structure, AMPs are characterized as α-helix, β-sheet,
extended, and loop, with α-helix and β-sheet AMPs being the most common [40]. The αhelical peptides are cationic and amphipathic with some level of hydrophobicity that
possess antimicrobial activity [41]. Some α-helical AMPs are rich in the amino acids, His
and Trp. Examples of α-helical AMPs are protegrin, magainin, and LL37 (a human
cathelicidin) [42]. AMPs classified under β-sheet contain at least two β-strands with
disulfide bonds between the strands [43]. Although most AMPs belong to one of the four
categories listed above, some do not belong to any of them [44], and can contain two
different structural components [45]. Among the four categories of AMPs, the α-helical
AMPs are one of the most studied types [46].
Mechanism of action of antimicrobial peptides. Most peptides only form their
active structure once they are interacting with their target membranes. Commerciallyavailable antibiotics target specific cellular activities, while AMPs are proposed to use a
multitude of complementary actions to cause cell death [47]. AMPs kill target cells by
disrupting the membrane integrity by inhibiting proteins, DNA and RNA synthesis, or by
interacting with specific intracellular targets. Due to their multi-hit mechanism, this
reduces the possibility of bacterial drug resistance in AMPs ultimately increasing the
efficiency of AMPs [48].
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AMPs initial interaction with the bacterial cell membrane occurs through electrostatic
bonding between the positively charged peptide and negatively charged components
located on the outer bacterial envelope [49]. Since AMPs are composed of cationic and
hydrophobic residues, there is a strong interaction with a bacterial membrane that
contains negatively charged lipids such as phosphatidylglycerol or cardiolipin [50]. The
most common explanation of AMPs selectivity for bacterial cells over host cells are the
difference in membrane interactions caused by the exposed anionic lipid content present
in bacterial membranes [3]. Since electrostatic interactions play a key role in the binding
of AMPs to bacterial membranes, the interactions with the neutral
phosphatidylcholine/cholesterol-rich surfaces of prokaryotic membranes are significantly
weaker.
Although the mechanism of action for AMPs are not fully understood, there are many
proposed pathways to disrupt the bacterial cell membrane that AMPs use. A few models
include the barrel-stave pore, the toroidal pore, and the carpet model [51]. In the barrelstave pore model, peptides are shown interacting laterally with one another to form a
structure similar to a membrane protein ion channel, while in the toroidal pore model
peptide-peptide interactions are not present. Instead, the peptides induce a curvature of
the bilayer to create a high curvature form. The major difference between these two
models are that the barrel-stave pores are working with the bilayer hydrocarbon core,
ultimately using it as a template for peptide-self-assembly, while the toroidal pores are
working against the core, disrupting the segregation of the polar and non-polar parts, to
provide a surface where lipid hydrocarbons and headgroups are able to interact favorably
[50]. The carpet model was proposed in 1996 by Shai to explain the mechanism of action
5

of a mammalian cecropin P1 on model membranes. Their proposed model consists of the
peptide micelle coating a small area of the membrane surface where AMP molecules
penetrate the lipid bilayer, letting pore formation occur [52]. This method leaves behind
holes or pores in the membrane [53]. The AMP is only active when aggregation of
peptides align (to form a carpet-like structure) with the lipid bilayer [54].
Physiochemical properties of antimicrobial peptides. Since AMPs are composed
of amino acids, modification to their sequence is relatively easy to perform, which helps
to modify activity and target spectrum, along with improving stability of AMPs [55-56].
Important physiochemical properties of AMPs for their antimicrobial activity and target
specificity include size, net charge, hydrophobicity, amphipathicity, and solubility [46].
Length is an important factor in AMPs because when forming an amphipathic structure
with hydrophobic and hydrophilic faces on opposite sides, at least 7-8 amino acids are
needed. Although length effects its 3D structure and potential mode of action, it may also
affect its cytotoxicity [57]. A study showing a shortened melittin with 15 residues at its
C-terminal exhibited at least 300 times less toxicity to rat erythrocytes, compared to its
original form [58]. In another study, a derivative of HP-A3, with deletion of the NTerminal random coil (residues 2-5; called A3-NT) exhibited higher antimicrobial
activity with no hemolytic activity even at high concentrations of peptide [59]. These
examples show length should be considered while designing a low toxicity synthetic
peptide.
The sum of all charges of ionizable groups of the peptide is known as the net charge.
The charge can vary from negative to positive but is the main factor for initial interaction
between negatively charged bacterial cell membranes. Most α-helical cationic AMPs
6

contain at least a net positive charge of at least +2 [181]. Many studies have shown net
charge can affect the AMPs hemolytic and antimicrobial activities, to selectively kill
microbes with minimal effects on the host cells [4]. For example, a study performed by
Dathe et al. showed that an increase in net charge of magainin 2 from +4 to +5 increased
antimicrobial activity. However, an increase to +7 did not increase the observed
antimicrobial activity but did increase hemolytic activity [182].
Hydrophobicity has also shown influences the activity and selectivity of AMPs.
Natural AMPs contain about 50% hydrophobic residues in its sequence. It has been
shown that when the hydrophobicity increases on the positively charged side of an AMP
below a threshold can increase its antimicrobial activity, and when hydrophobicity is
decreased it reduces the antimicrobial activity [42, 60]. There have also been studies
showing that hydrophobic residues play an important role in hemolytic activity [183]. For
example, a study performed by Chang et al.showed peptides containing hydrophobic
residues of N-terminal hydrophobic core were involved in the hemolytic and bactericidal
activity. When they increased the hydrophobicity in the peptides tested, both bactericidal
and hemolytic activity was reduced. AMPs do have an optimal window of
hydrophobicity, and once passed it has a rapid decrease in activity [61].
Another important property of AMPs is amphipathicity. This helps ensure activity
and interaction with bacterial cell membranes. A study performed by Fernandes-Vidal et
al. had shown amphipathicity helps create a strong partition for the AMP to get into the
membrane interface [62]. This makes amphipathicity more important than hydrophobicity
when binding to bacterial cell membranes.
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AMPs solubility in aqueous environments are essential due to initial interactions with
the bacterial membrane. If the AMP molecules aggregate, it will lose its ability to interact
with the bacterial cell membrane, making solubility an important factor. Each of these
properties, length, net charge, hydrophobicity, helicity, amphipathicity, and solubility
should be taken into consideration when designing a novel peptide. AMPs have evolved
to balance each of these properties to maintain optimal function.
Modifications to antimicrobial peptides. There are many factors that affect the
activity of AMPs. It has been shown that modification of an AMPs properties can alter
other properties. Even a small change in the primary sequence has been shown to affect
physiochemical properties necessary for the activity of an AMP to interact with its target
cell [46]. Although many AMPs are directly synthesized in their active forms, some
AMPs require post-translational modification to perform their intended functions.
Venom-derived antimicrobial peptides. A particular category of AMPs that have
been studied and modified, are venom-derived peptides. Venoms contain a mixture of
peptides, proteins, and enzymes serving as either predation and defense against microbes
and predators [63]. Although there are many venom-derived peptides that have
antimicrobial activity, not all peptides are AMPs or even biologically active when
extracted. Venoms are comprised of a diverse array of different biologically active
peptides with a myriad of activities and targets including neurotoxins, membrane
permeabilizing agents, and GPCR agonists and antagonists [64-65]. In fact, venom
peptides appear to have evolved from a somewhat small number of structural frameworks
that are well suited to addressing the crucial issues of potency and stability [65]. These
bioactive peptides are small in size, relatively easy to synthesize in the lab, and have
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significant structural stability and target specificity making them a novel antimicrobial
component [66].
To survive chemical degradation in solution at ambient temperature and enzymatic
degradation by processing proteases present in venom, these venom-derived peptides
must be sufficiently stable [67]. Post-translational modifications (PTMs) and/or disulfide
bonds is how these peptides are able to achieve this type of stability. Common PTMs
include amidation (C-terminal), sulfation (Tyr), bromination (Trp), glycosylation (Thr),
γ-carboxylation (Glu), hydroxylation (Pro), pyroglutamation, N-C-cyclization, and
isomerization to ᴅ-amino acids [65]. These modifications introduce specific enzymes at
particular locations during the production of venom peptides, which can help enhance
bioavailability and potency along with stability. Although many of these modifications
help enhance peptide properties, they are not always optimal for the requirements
associated with potential therapeutic applications. Issues such as formulation, cost of
production, stability, selectivity, and mechanism of action are associated with using
venom peptides as therapeutics.
A significant issue with venom peptides is their bioavailability, which is generally
poor due to their size (10-40 amino acids) and hydrophilic nature [65]. This issue makes
it necessary for the peptide to be administered to the site of action by injection
(intravenous, intrathecal, intraperitoneal, intramuscular, subcutaneous, or epidural). There
have been many emerging approaches, such as lipophilic modifications, to improve
peptide delivery to help eventually allow oral delivery to central and peripheral target
[68]. Venom-derived peptides overall have beneficial properties such as stability, and
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target specificity which are useful in antimicrobial use. However, issues including safety,
pharmacokinetics, and delivery would need to be addressed before therapeutic use.
Background of ionic liquids. In addition to discovering new antimicrobials, there
have been also studies performed to enhance antimicrobial efficacy with commercially
available antibiotics in combination with other molecules. An example of a widely used
combinatorial formulation is amoxicillin with clavulanic acid [69]. The amoxicillin is
used to inhibit peptidoglycan synthesis while clavulanic acid inhibits the β-lactamase
enzyme which degrades amoxicillin. Other approaches take two molecules that
independently exhibit antimicrobial activity and combine the dose for treatment [70-71].
The majority of combination therapies are designed to act via different mechanisms,
ultimately enhancing the activity of the other. Unfortunately, no clear best practice using
these therapies have emerged, only case-specific protocols.
Ionic liquids (ILs) are a class of salts that exist in liquid form at room temperature
[72-73]. ILs contain a cation and anion pair which can be changed, creating a wide range
of IL species. Chemical properties of ILs include low melting point, negligible vapor
pressure, and exceptional solvation potential. ILs have received attention as a potential
biomaterial that can undergo modification (via changing their cations and anions) for
various biomedical applications [74-75]. Other applications of ILs include use in
pharmaceutics and medicine [76], and the extraction and separation of biomolecules [77].
Studies have also shown ILs ability to both stabilize and destabilize protein structures,
exhibit sensitive protein interactions, enhance enzymatic activity, and impact DNA
structure [78-80]. However, literature indicates that not all ILs behave similarly and that
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the effects on biomolecules are dependent on the molecular identity of the components of
the ILs.
Ionic liquids as antimicrobials. The interactions between ILs in aqueous
solution and lipid bilayer membranes have helped guide the development of IL-based
drug formulation and drug-delivery applications [76, 81-84]. Ultimately opening research
avenues for IL-based antibiotics and antibiotic-IL combinatorial therapies. There have
also been reports highlighting both experimental and computational studies on how ILs
interact with lipid bilayers [85-86]. Hydrophobic ILs are able to insert themselves into
lipid bilayers, leading to bilayer reorganization [87-89]. ILs have also exhibited
antimicrobial effects with addition of enzyme-hydrolyzing groups, alkyl chains, and
stable anions [90]. Additionally, a tetracycline-based IL has been shown to insert into
liposome membranes with important drug-delivery and antibiotic implications [83]. The
highly recombinant nature of ILs makes amenable to formulating “designer” reagents to
treat specific cell types: rearranging both the anion and cation a can allow for highly
specific, tailored applications in different organisms [82]. Previous studies demonstrated
that IL with imidazolium-based cations were successful in permeating the membranes of
bacteria, yeast, and red blood cells [91]. Other ILs have been shown to exhibit
antimicrobial activity alone, or impact the manner in which antimicrobials interact with
lipid bilayers [92]. Additionally, micelle formation can occur in these molecules through
the interactions of the IL alkyl chains, which can influence the interactions with cellular
membranes [93].
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Chapter 2
Investigation of the Sequence-Structure-Activity Relationship in Ponericin L1 from
Neoponera goeldii
Introduction
There are three categories of insect AMPs; Cecropins, Defensins, and peptides
with an overrepresentation of Proline and/or Glycine residues [94]. They are
separated based on their amino acid sequence and structure. Cecropins are linear
peptides that lack cysteine residues but form an α-helix structure. Defensins consist of
6-8 conserved cysteine residues, are stabilized by 3 or 4 disulfide bridges and contain
3 domains that have a flexible amino-terminal loop. Cecropins are shown to exhibit
antimicrobial activity against both Gram-positive and Gram-negative bacteria, while
Defensins selectively kill Gram-positive, and glycine-rich and proline-rich kill Gramnegative strains [95]. Insect AMPs are considered very potent due to their IC50 range
being in the submicromolar or even low micromolar range, even though there are
none yet on the market [96]. Ponericins have been known to be one of the most
explored insect AMPs, along with cecropins, drosocin, attacins, diptericins, defensins,
drosomycin, and metchnikowin [97-98].
Background on ponericins. Ponericins are AMPs that were isolated from the
venom of the predatory ant Neoponera goeldii (previously misclassified as
Pachycondyla goeldii). There are fifteen novel ponericins extracted that exhibit both
antibacterial and insecticidal properties [99]. Ponericins are classified as either G, W,
and L based on their primary structure. All three classes are cationic, amphiphilic
peptide sequences, with nearly all (12/15) containing a Trp residue in the N-terminal
12

region. Ponericins share high sequence similarities with known peptides; the G
ponericins are like cecropins, W ponericins have similarities with gaegurins and
melittin, and finally, L ponericins are similar to dermaseptins. All ponericins exhibit
an α-helical structure in cell membranes [100].
The G family of ponericins share about 60% sequence similarity with cecropins.
Cecropins exhibit broad spectrum antimicrobial activity against bacteria and fungi
without affecting host cells [101-102]. The W family of ponericins have common
properties due to their high sequence similarities. They are active against bacteria and
yeast but also show hemolytic and insecticidal activities. Ponericins W have about
70% similarity in sequence to gaegurin 5 and melittin. Both the ponericin G and W
families contain a Pro residue near the middle of the sequence in 11 of 13 sequences
(the others G6 and G7 have the Pro residue near the C-terminus due to the shorter
overall length). There have been studies performed on both G- and W-families of
ponericins [103-108], along with novel peptides that show similarity to the G- and Wfamilies [109-111].
The L-family ponericins, are the most poorly understood peptides and consist of
ponericin L1 and L2. Both L1 and L2 share sequence similarities with dermaseptin 3
and 5 [112-114]. The only report of the activity and characteristics of these peptides
are found in the original report by Orivel et al., and even in this study, only ponericin
L2 was examined. Ponericin L2 was shown to have broad-spectrum antibacterial
activity with no hemolytic activity. The peptide adopted a random coil conformation
in water (possibly polyproline-II helix). Ponericin L1 differs from L2 by only a single
amino acid at position 9, with L1 containing a Met while L2 contains an Ile. There is
13

a general lack of understanding and investigation of the L-family of ponericins and
their mechanism.
Role of cationic groups in AMPs. The cationic charge of an AMP is a key
component in the initial binding between the peptide and the bacterial cell membrane
[115]. However, many studies have shown that the position of cationic and
hydrophobic residues can significantly impact the selectivity and antimicrobial
activity of AMPs [116-120]. Therefore, the role of cationic residues in context of
specific hydrophobic amino acids may also have an impact on activity. Cationic chain
length tolerance may also be influenced by corresponding hydrophobic molecules’
size and shape. This study focuses on the characteristics and behavior of ponericin L1
with extension to investigate the role of cationic residues and overall charge effects
on activity.
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Figure 1. Peptide Sequences and Helical Wheel Diagrams. Helical wheel diagram of L1,
A, L1-Q, B, and L1-K, C. Cationic residues are shown in blue, anionic in red,
hydrophobic in green, polar uncharged in yellow, and aromatic are in purple. Peptides
sequences and relevant properties are shown below the helical wheels. Helical wheel
representations were made using MPEx [121]

Materials and Methods
Peptide preparation. Peptides L1-Q, L1-K, and L1-O (ornithine) were
synthesized using standard FMOC-chemistry in-house. Peptide L1-R was purchased from
Genscript (Piscataway, New Jersey). The peptide L1-X (L1 with lysine replaced with diamino-propionic acid, Dap) presented significant synthetic challenges and was thus
purchased from Synthetic Proteomics (Carlsbad, California) along with the L1 parent
sequence. All peptides were subsequently purified via RP-HPLC using a Zorbax C3
column and eluted by a linear gradient of water to acetonitrile (both supplemented with
0.1% TFA). Peptide identity was confirmed using ESI-MS. HPLC fractions containing
15

peptide were pooled, lyophilized, and stored at −20°C. Prior to use, peptides were
dissolved in 3:1 H2O:ethanol to create a stock solution of 150 to 200 μM and stored at
4°C.
Lipid preparation. Lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC;
PC), 1,2-dioleoyl-sn-glycero-3-phospho-(10 -rac-glycerol) (DOPG; PG), and 1palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE; PE) were purchased from
Avanti Polar Lipids (Alabaster, Alabama), and stored as stocks in chloroform at −20°C.
Lipids were prepared as 100% DOPC, 3:1 DOPC:DOPG (PC:PG), or 3:1 POPE:DOPG
(PE:PG). Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Chem-Impex Int'l INC.), orthonitrophenyl-β-galactoside (ONPG) (Research Products International Co.), nitrocefin
(Biovision, Milpitas, California). All other chemicals and reagents were from Thermo
Fisher Scientific (Waltham, Massachusetts), VWR (Radnor, Pennsylvania), or SigmaAldrich (St. Louis, Missouri). Small unilamellar vesicles (SUVs) were formed by
sonication or by ethanol dilution methods. In all cases, appropriate volumes of lipids in
chloroform were mixed in a glass test tube, dried under a gentle stream of N2, and further
dried under vacuum for at least 1 hour to create a lipid film in the tube. For the ethanol
dilution vesicles, 10 μM of pure ethanol was added to the film, vortexed until the film
was dissolved at which point the appropriate amount of PBS was added while vortexing.
For sonicated vesicles, the PBS was added directly to the lipid film and vortexed to create
multilamellar vesicles (MLVs). This MLV suspension was then subjected to sonication in
a high-powered bath sonicator (Avanti Lipids) for 20 minutes to create SUVs.
Fluorescence spectroscopy. All fluorescence spectroscopy was performed on a
JY-Horiba Fluoromax4 instrument with excitation and emission slit widths at 2.5 nm.
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Measurements were taken in semi-micro quartz cuvettes. Spectral barycenters were
calculated using the following formula: B = Pλ i Pi ð1Þ where B is the barycenter, λ is
the wavelength, and i is the intensity at that wavelength. The summation is carried out
over the entire emission spectrum collected, in this case 300 to 400 nm.
Binding experiments. Lipid binding assays were carried out as performed
previously [122]. Briefly, the samples contained 2 μM peptide in PBS buffer (150 mM
NaCl, 50 mM Na2HPO4; pH 7.0) and were titrated with a lipid vesicle stock (0.5 or 1.0
mM concentration). All binding assays used excitation at 280 nm and an emission range
of 300 to 400 nm. The spectra were corrected from the background and the dilution after
each addition.
Red-Edge Excitation Spectroscopy experiments. Red edge excitation shift
(REES) experiments used excitation at 280, 290, 295, 300, 305, and 307 nm with an
emission range of 310 to 410 nm. Again, samples contained 2 μM peptide in PBS buffer.
The spectra were corrected from the background and the dilution after each addition.
TCE quenching. Trichloroethanol (TCE) quenching assays were performed by
titrating 10 μL aliquots of 10 M TCE (Alfa Aesar, Haverhill, Massachusetts) into samples
containing 2 μM peptide in PBS (150 mM NaCl, 50 mM Na2HPO4; pH 7.0). The Trp
fluorescence emission was recorded after each addition with excitation at 280 nm and
emission at 340 nm. Data were corrected from background and dilution. The SternVolmer quenching constant (Ksv) was determined from the slope of a linear best fit
equation to the data.
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Acrylamide quenching. Acrylamide quenching was performed by titrating 10 μL
aliquots of 4 M acrylamide and measuring Trp emission after each addition. Samples
contained 2 μM peptide and 250 μM total lipid in PBS. The Trp fluorescence emission
was recorded after each addition with excitation at 295 nm and emission at 340 nm. Data
were corrected for background, dilution, and inner filter effects in the excitation path as
described previously [123]. The Ksv was calculated as above.
DQA experiments. Dual quencher analysis (DQA) experiments were performed
as previously described [123]. Briefly, samples were prepared as above, with the
exception that in one set of samples 10% of the lipid (molar basis) was replaced with the
quencher 10-doxyl nonadecane (10-DN). Samples contained either no 10-DN (F0) or 20
μM 10-DN (Fdox). Similarly, peptide was added to a final concentration of 2 μM and
allowed to equilibrate for 30 minutes. Fluorescence measurements were taken, and then
50 μL of acrylamide was added to each F0 sample, allowed to equilibrate, and
remeasured. After inner filter correction (only for acrylamide containing samples) and
background subtraction, the Q-ratio was calculated as previously described [123].
Circular dichroism spectroscopy. Circular dichroism (CD) spectra were
collected using Jasco J-810 spectropolarimeter. Samples contained 5 μM peptide in 0.1X
PBS buffer or 0.1X PBS buffer with 50% trifluoroethanol (Alfa Aesar). Lipid containing
samples consisted of 200 μM lipid vesicles with 3 μM peptide in 0.1X PBS buffer. Each
sample had 64 scans performed with correction from background without peptide.
Bacterial culturing. Bacteria were streaked on LB-Miller agar plates from a
frozen glycerol stock made from the original samples shipped from CGSC (Coli Genetic
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Stock Center, Yale University) or ATCC (American Type Culture Collection)
(Escherichia coli D31 CGSC 5165 [124], Staphylococcus aureus ATCC 35556,
Pseudomonas aeruginosa PA-01 ATCC 47085 [125], Acinetobacter baumannii ATCC
19606). An overnight was prepared using a single colony of each bacterial strain into
fresh LB broth and placed into a shaking incubator 37 C at 225 rpm for ~18 hours. After
incubating overnight, a fresh 1:200 dilution was made in LB broth and used for the
experiment.
Minimal Inhibitory Concentration (MIC)/Minimal Bactericidal
Concentration (MBC). Minimum inhibitory concentration (MIC) was performed using
mid-log phase bacteria diluted to 5 × 105 CFU/mL. Then, 90 μL of the diluted culture
was added to the wells of a sterile 96-well plate containing serially diluted aliquots of
each peptide for a total volume of 100 μL. The plate was incubated at 37 C for 18 hours.
After incubation, bacterial growth was determined by measuring OD600 using a
Spectramax M5 multimode plate reader. Minimum bactericidal concentration (MBC) was
performed by removing 1 μL of culture from each well of the MIC plate and plating on a
fresh LB agar plate which was subsequently incubated overnight at 37 C. MBC was
determined by the growth or absence of growth from each well on the agar plate.
Lipid vesicle leakage. Lipid films were prepared as described above. A 75 mM
stock of calcein was prepared in HEPES buffer, pH 7. The lipid film was resuspended in
700 μL of calcein solution for a final lipid concentration of 20 mM. The resuspended
lipid vesicle sample was subjected to seven freeze-thaw cycles by alternating between a
liquid N2 bath and a 42 C water bath, culminating with a final thaw of the sample. The
vesicles were then sonicated using a VCX 130 Probe sonicator (Sonics & Materials, Inc.)
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for 1 minute, using 1 second pulses at 45% intensity. Vesicles were separated from
unincorporated calcein by size exclusion chromatography using G25 Sephadex. The
column was equilibrated in HBS (50 mM HEPES, 150 mM NaCl, pH 7) under gravity
flow for approximately 1 hour before the vesicle solution was loaded onto the column.
Upon loading, ~40 1 mL Fractions were then collected from the column. Fractions
containing vesicles with entrapped calcein exhibited a cloudy, orange color and were
separated from the unincorporated calcein, which has a clear yellow color. Vesicles were
used on the same day as prepared. Vesicle concentrations/dilution factor were determined
using a ratiometric assay with vesicles containing a known concentration of fluorescent
lipid [126]. The two most concentrated fractions were diluted 1:1 with HBS buffer.
Solutions were dispensed into a 96 well plate in the subsequent order: 10 μL of peptide
with serial dilutions starting at a final concentration from 15 μM (excluding the last row
which had 10 μL of 0.01% Acetic Acid as a negative control), 20 μL of the diluted
vesicle fractions, and 70 μL of PBS buffer (50 mM sodium phosphate, 150 mM sodium
chloride pH 7) for a final lipid concentration of ~200 μM. The samples were excited at
495 nm and fluorescence emission was measured at 520 nm using a 510 nm cutoff filter
in a Spectramax M5 (Molecular Devices) multimode plate reader. Following the initial
reading, 20 μL of Triton X-100 was added the last row as a positive control. The plate
was placed on a plate shaker for 1 hour at 400 rpm, shielded from light. Calcein
fluorescence emission was then remeasured and used as the 100% leakage normalization
value. Data reported are the average of three replicates.
Bacterial inner membrane permeabilization assay. An overnight culture of E.
coli D31 was prepared by inoculating a single colony into fresh LB broth and placed in a
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37 C shaking incubator (225 rpm) for ~18 hours. Following the overnight incubation, a
1:250 dilution of the culture to fresh LB broth was made. This was supplemented with
100 μL of 100 mM IPTG to induce the expression of β-galactosidase. The dilution was
incubated with shaking until an OD600 of 0.2 to 0.4 was reached. Solutions were
dispensed into a 96 well plate in the subsequent order: 10 μL of peptide with serial
dilutions starting a final concentration from 15 μM (excluding the last row which had 10
μL of 0.01% acetic acid as a negative control), 56 μL Z-buffer (60 mM Na2HPO4, 40
mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM β-mercaptoethanol, pH 7), 19 μL of
E. coli culture, and 15 μL of 4 mg/mL ONPG dissolved in Z-buffer. Immediately
following the addition of ONPG, absorbance was recorded at 420 nm every 5 minutes for
90 minutes. The detergent cetyltrimethylammonium bromide was added in place of the
peptide as a positive control. Data reported are the average of three replicates.
Bacterial outer membrane permeabilization assay. An overnight culture of E.
coli D31 was prepared by inoculation a single colony into fresh LB broth with 100
μg/mL ampicillin (LB-Amp) and placed in a 37 C shaking incubator (225 rpm) for ~18
hours. Following the overnight incubation, a 1:250 dilution of the culture to fresh LBAmp was made. The dilution was incubated with shaking until an OD600 of 0.2 to 0.4
was reached. The bacterial culture was then centrifuged at 2500 rpm for 15 minutes in a
tabletop clinical centrifuge. The supernatant was discarded and the pellet was
resuspended in an equal amount of PBS (100 mm NaH2PO4, 200 mM NaCl, pH 7). The
experimental samples were prepared in a 96 well plate in the subsequent order: 10 μL of
peptide with serial dilutions starting at a final concentration from 15 μM (excluding the
last row which had 10 μL of 0.01% acetic acid as a negative control), 80 μL of the
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resuspended E. coli culture, and 10 μL of 50 μg/mL Nitrocefin in PBS. Immediately
following the addition of nitrocefin, absorbance was recorded at 486 nm every 5 minutes
for 90 minutes. The antimicrobial polymyxin B was used as a positive control. Data
reported are the average of three replicates.
Hemolysis assay. Hemolysis of human red blood cells (RBCs) was used to
quantify membrane destabilization by leakage of hemoglobin. Blood was collected in
vacutainer tubes (10 mL) with EDTA coating as an anticoagulant (provided by the
Rowan Department of Health and Exercise Science from a fresh draw ~1 hour prior to
use, IBC protocol 2019-11). A 7 mL aliquot of whole human blood was mixed with 7 mL
of sterile PBS. The solution was then sedimented via centrifugation for 7 minutes at 2500
rpm. The supernatant was removed and the pellet containing RBCs was resuspended to
the original volume of 14 mL with PBS. This process was repeated three times. The final
cell pellet was resuspended to a final volume of 14 mL and 90 μL of this cell suspension
was added to all wells of a conical-bottom 96-well plate. Prior to addition of RBCs, 10
μL of serially diluted peptide or the detergent Triton-X 100 (as a positive control) were
added to the wells. The covered plate was placed into a shaking incubator for 60 minutes
at 37 C while shaking (150 rpm). The conical plate was centrifuged for 10 minutes at 200
rpm and 4 C. Subsequently, 6 μL of the supernatant was added to 94 μL of fresh PBS in
wells of a flat-bottom plate. Analysis of hemolysis was performed by measuring
absorbance at 415 nm using a Molecular Devices Spectramax M5 plate reader. Percent
hemolysis was calculated based on the absorbance of each well compared to those wells
with no additive and those with Triton-X 100. All data reported are the average of three
replicates.
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Results
Peptides. The original L1 sequence and all of the variants tested are listed with
net charge, and molecular mass in Figure 1. Standard amino acid abbreviations are used
except in the case of L1-O and L1-X, which represent the cationic substitutions of lysine
with ornithine or di-amino-propionic acid, respectively. Solid-phase FMOC chemistry
methods were used to synthesize all peptides. Peptides were purified using HPLC. The
helical wheel diagrams depict the orientation of amino acids along the helical axis, also
shown in Figure 1. In general, the original L1 sequence does not adopt a canonical
amphiphilic helix with a hydrophobic face and a cationic face. Instead the L1 peptide in
helical conformation exhibits a hydrophilic face, but the cationics are flank that face with
a number of polar, uncharged, and the lone anionic group interspaced on this face. Like
L1, numerous venom peptides do not have a strictly cationic face, but instead a polar face
with cationic and polar uncharged residues [127-129].
Antimicrobial activity. Antimicrobial activity of L1 and variants were tested
using a broth microdilution assay to determine the MIC (Table 1). All peptides exhibited
similar (fourfold range) of activity against E. coli, and all but L1-X showed similar
activity against A. baumannii. In contrast, the parent L1 sequence showed weak activity
against S. aureus and P. aeruginosa, while L1-R, L1-Q, and L1-K were more effective
against S. aureus, while L1-K and L1-Q were also very active against P. aeruginosa. The
concentration required to kill the bacteria in solution, or MBC, was also measured by a
plating assay after the MIC assay. The MBC values for each peptide was equal to or
about 2x greater than the MIC. These results indicate that the L1 peptides are likely
acting in a bactericidal mechanism, instead of a bacteriostatic mechanism. A bactericidal
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mechanism is assumed because the bacteria is not growing when removed from the
antimicrobial peptide solution and placed on a fresh LB-agar plate.

Table 1
MIC and MBC (µM)

L1
L1-Q
L1-K
L1-R
L1-O
L1-X

E.coli
S. aureus
MIC MBC MIC MBC

P. aeruginosa
MIC
MBC

A. baumannii
MIC
MBC

0.94

0.94 15.00 15.00

15.00

15.00

1.88

1.88

0.94

0.94

1.88

1.88

7.50

7.50

0.94

1.88

1.88

1.88

3.75

3.75

3.75

3.75

0.94

0.94

0.94

0.94

1.88

1.88

15.00

15.00

0.94

1.88

1.88

1.88

>15

>15

15.00

15.00

1.88

1.88

3.75

7.50

>15

>15

15.00

>15

>15

>15

Note: Abbreviations: MIC, minimal inhibitory concentration; MBC, minimal bactericidal
concentration.

Solution behavior. The antimicrobial activity of most AMPs begin with the
peptide in solution before interacting with the bacterial membrane, including the L1
peptide. Behavior of the peptide in solution and how sequence variation can affect these
properties play a role in the equilibrium between the free and bound states of the peptide.
Red-Edge Excitation Spectra (REES) can be used to indicate the mobility of the Trp
fluorophore, and yield insights into relative changes in the peptide aggregation and/or
oligomerization [130-131]. REES results are shown in Figure 2A. All peptides displayed
some extent of increase in the spectral barycenter as a function of excitation wavelength.
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This indicates some level of restricted motion around the Trp fluorophore. The L1, L1-K,
L1-R, and L1-X sequences showed significant shifts in the emission, between 7 and 11
nm at the highest excitation wavelength (307 nm), shown in the inset of Figure 2A. The
red edge effects at this magnitude are strongly indicative of restricted motion around the
Trp, likely caused from peptide aggregation or oligomerization.
Quenching of Trp fluorescence by TCE was also performed to investigate the
aggregation of L1 and variants. TCE has been shown to partition the interior of protein
aggregates and quench Trp more efficiently at the interior of these aggregates. The SternVolmer quenching constant, otherwise referred to as Ksv, is calculated from the slope of
a linear fit to the quenching data, and was used to analyze the quenching. A higher Ksv
value indicates increased Trp quenching. TCE quenching pattern determined by Ksv is
shown in Figure 2B (as well as Table 2). Comparing results of TCE to REES there is
some difference. L1-X and L1-K, which showed significant REES were also strongly
quenched by TCE. On the other hand, L1 and L1-R, which also showed significant
REES, were only minimally quenched by TCE. These results indicate potential
differences in the packing or organization of the L1 solution aggregation state as a
function of the sequence.
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Figure 2. Peptide Solution Assays. Red-edge excitation shift (REES), A, and
trichloroethanol (TCE) quenching, B. The inset in panel A depicts the total shift for each
peptide. In both panels, L1 is shown in light blue, L1-Q in orange, L1-K in gray, L1-R in
yellow, L1-O in dark blue, and L1-X in green. All data are averages of three samples
with correction from the background and error bars represent the SD.
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Table 2
TCE Quenching

Sequence
L1
L1-Q
L1-K
L1-R
L1-O
L1-X

-1

0.30
15.35
17.63
4.23
10.97
10.50

Ksv (M )
±
±
±
±
±
±

0.04
3.75
1.21
2.78
1.25
2.53

Interactions with lipid bilayers. A critical early step in the widely accepted
membrane-permeabilization mechanism for AMPs is the peptide interaction with lipid
bilayers. The affinity and orientation of membrane interacting peptides has been shown to
be impacted by bilayer thickness, headgroup composition, pH, and other factors. As
compared to a traditional host defense peptide, L1 is a venom-derived peptide and despite
its net positive charge there is no inherent evolutionary need for it to preferentially
interact with anionic bilayers.
Affinity for lipid bilayers was investigated using the environmental sensitivity of
the naturally occurring Trp residue in the L1 sequence. When the local environment
around the Trp shifts from more polar (aqueous solution) to less polar (surface of the
bilayer or imbedded in bilayer core), the Trp fluorescence emission spectrum exhibits a
shift from “red” to “blue”. The shift of the spectrum is determined by the shift in the
spectral barycenter, or center of mass, as a function of titrated lipid vesicles [115]. The
spectral barycenter was calculated using the intensity-weighted average over the range
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wavelengths collected [132]. The data from these binding experiments are shown in
Figure 3, with representative spectra of the free and bound peptides shown in Figure 4.
All variants exhibited binding to all lipid compositions tested (100% PC; 3:1 PC:PG; 3:1
PE:PG; and 7:3 PC:Cholesterol). Higher binding affinity was shown to bilayers
containing anionic lipids (note the difference in X-axis scaling in Panels A and C vs B
and D in Figure 3). The peptide L1-X, containing the shortest side chain, exhibited a
lower total shift in barycenter when completely bound in all lipids, indicating this
substitution affects the depth of insertion into the bilayer. Although there was a lower
total shift, it did not seem to have an effect on the general affinity for vesicles with
anionic lipids.
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Figure 3. Binding to Lipid Vesicles. Peptide binding was assayed using Trp fluorescence
emission by titrating SUVs into a sample containing 2 μM peptide. The spectral
barycenter was calculated after each addition of lipid vesicle and the Δbarycenter is the
difference between the initial barycenter and that after each addition. Binding was
assayed with, A, PC, B, 3:1 PC:PG, C, 3:1 PC:Cholesterol, and, D, 3:1 PE:PG. In all
panels, L1 is shown in light blue, L1-Q in orange, L1-K in gray, L1-R in yellow, L1-O in
dark blue, and L1-X in green. Note the difference in X-axis scaling for panels A and C vs
B and D. All data are averages of three replicates and the error bars represent the SD.
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Figure 4. Normalized Trp Emission Spectra. L1 peptide data shows before (red) and after
(blue) interacting with lipid vesicles. Data are representative spectra after subtraction of a
background spectrum. All samples contained 2 μM peptide and 300 μM lipid ‐ (A) PC,
(B) PC:PG, (C) PC:Chol, (D) PE:PG.

A series of fluorescence quenching experiments were performed to further
investigate how the peptides interact with bilayers. Acrylamide quenching was performed
on the peptides in solution and when bound to bilayers with various composition. Trp
residues that are exposed to the aqueous environment are quenched efficiently by
acrylamide. Acrylamide will not quench Trp buried in the nonpolar core of the bilayer.
Thus, the quenchability of the Trp is directly related to its exposure to the aqueous
environment. The Stern-Volmer, or Ksv, quenching constants for the L1 peptides
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quenched by acrylamide under different conditions are shown in Table 3, with full
quenching profiles shown in Figure 5. To calculate the Ksv, the equation used is:
1+

=

[ ], where F0 is the fluorescence intensity in the absence of the quencher Q, and

F is the fluorescence intensity in the presence of different concentration of Q. The
constant Ksv is the product of the true quenching constant kq, and the fluorescence
lifetime in the absence of the added quencher, τ0 [133]. In all conditions, the peptides
show a decrease in the Ksv between aqueous and any bilayer-interacting condition,
supporting the binding results showing the peptides interact with all bilayers.
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Figure 5. Acrylamide Quenching of L1 Peptides. Data shows L1 peptides in (A) PBS
buffer, (B) PC vesicles, (C) PC:PG vesicles, (D) PC:Chol vesicles or (E) PE:PG vesicles.
All samples contained 2 μM peptide and 250 μM lipid (for those with vesicles). Data are
corrected for inner filter effects and are background subtracted. Data represent the
average and SD of 3‐6 samples.
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Table 3
Fluorescence Quenching
-1

Q-Ratio

Acrylamide Quenching (Ksv (M ))
PBS
DOPC PC/PG PC/PG/PE PC/Chol PE/PG
L1 10.14 ± 1.15 2.49 ± 0.32 2.08 ± 0.27 1.89 ± 0.28 3.18 ± 1.27 1.51 ± 0.08
L1-Q 15.43 ± 0.17 1.67 ± 0.19 1.23 ± 0.01 1.52 ± 0.25 1.72 ± 0.16 1.63 ± 0.08
L1-K 16.48 ± 1.97 1.44 ± 0.13 1.07 ± 0.07 1.13 ± 0.63 1.77 ± 0.37 1.86 ± 0.01
L1-R 18.90 ± 1.49 4.64 ± 0.65 2.20 ± 0.21 0.60 ± 0.27 4.82 ± 0.81 1.46 ± 0.23
L1-O 22.68 ± 0.84 3.86 ± 0.09 2.96 ± 1.40 0.46 ± 0.63 4.54 ± 1.14 2.47 ± 0.39
L1-X 19.69 ± 4.29 7.09 ± 2.38 4.28 ± 1.17 4.72 ± 0.33 7.56 ± 0.20 4.17 ± 0.72

DOPC
3.46
1.68
4.09
3.13
4.01
4.08

PC:PG
1.29
2.12
2.51
0.13
1.86
1.86

PE:PG
0.15
0.80
1.78
1.00
1.41
7.16

Note: Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG, 1,2dioleoyl-sn-glycero-3-phospho-(10 -rac-glycerol). Data are averages of three to six
replicates with SD.

An extension of the acrylamide quenching assay is the DQA assay, which utilizes
acrylamide and a second, membrane-imbedded quencher, 10-DN. Although, acrylamide
is a widely used quencher of Trp, it is unable to efficiently quench the fluorescence of
Trp residues that are deeply submerged in the core of a bilayer [134-135]. This is why the
novel Trp quencher, 10-DN is used alongside acrylamide. 10-DN is a highly hydrophobic
molecule that contains a nitroxide-bearing doxyl group, which helps it strongly quench
Trp fluorescence [136-137]. The ratio of quenching between each quencher is directly
dependent on the Trp depth in the bilayer, which can help determine the orientation in the
bilayer. This can qualitatively identify orientation differences between different bilayer
compositions [123]. In the DQA assay, the more exposed the Trp residue is to the
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aqueous environment, the higher the Q-ratio. All Q-ratios for the L1 variants are shown
in Table 3, with visuals in Figure 6. The Q-ratio for all peptides in DOPC were similar,
regardless of sequence or affinity, but lower values were shown for peptides in bilayers
with anionic lipids, except L1-X in PE:PG bilayers.

Figure 6. Dual Quencher Analysis of L1 Peptides. Q-ratios were calculated for peptides
bound to lipid vesicles containing DOPC (blue), 3:1 DOPC:DOPG (orange), or 3:1
POPE:DOPG (grey) bilayers. The Q-ratio is calculated from the ratio of F0/F values for
quenching by 10-doxyl nonadecane and acrylamide at fixed concentrations. F0/F values
are averages of three to five samples.

A fluorescent dye-release assay was used to investigate the ability of each peptide
to permeabilize model lipid vesicles. The fluorophore calcein undergoes self-quenching
when entrapped in the lumen of the vesicle, which exhibits low fluorescence emission
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increasing dramatically upon bilayer permeabilization and release of the fluorophore into
the aqueous surrounding. Peptides were exposed to lipid vesicles composed of PC,
PG:PG, or PE:PG lipid mixtures. The percent leakage was calculated based off a
subsequent treated of the vesicles with the bilayer disrupting detergent, Triton X-100.
Leakage data is shown in Figure 7. The L1 peptides, in all lipid compositions, did not
induce leakage to a large extent, however at the highest concentration tested, L1, L1-R,
and L1-Q induced up to ~ 15% leakage in vesicle that contained PC. Interestingly, none
of the peptides induced any discernable leakage in vesicles composed of PE:PG lipids
which are commonly found in bacterial membranes.
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Figure 7. Vesicle Permeabilization Assays. Peptide permeabilization of model lipid
vesicles determined by dye leakage assays using calcein. Vesicles were composed of, A,
PC, B, 3:1 PC: PG, C, 3:1 PE:PG. In all panels, data were normalized based on untreated
vesicles (0% leakage) and vesicles treated with the detergent Triton X-100 (100%
leakage). L1 is shown in light blue, L1-Q in orange, L1-K in gray, L1-R in yellow, L1-O
in dark blue, and L1-X in green. All data are averages of at least three replicates and the
error bars represent the SD.
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Interactions with cellular membranes. L1 peptides were investigated for the
ability to permeabilize natural bacterial and mammalian membranes. Peptide interactions
with model lipid vesicles is informative; however, model vesicles only replicate a small
fraction of the complexity of natural lipid membranes which inherently contain greater
lipid diversity, lipid asymmetry, and integral membrane proteins. Using chromogenic
substrates of enzymes localized in the E. coli periplasmic space (nitrocefin and βlactamase) or cytoplasm (ONPG and β-galactosidase), the peptide effects on the
permeability of the bacterial outer or inner membrane can be investigated. Outer
membrane permeability is shown in Figure 8A while inner membrane permeability is
shown in Figure 8B. Notably, these data represent snapshots of leakage after 30 minutes
of exposure to the peptides, but full 90-minute time course data is shown in Figure 9
(Outer membrane) and Figure 10 (Inner Membrane). All peptides exhibited the ability to
disrupt the outer membrane in a concentration dependent manner, although L1-X only
did so at the highest concentration tested (Figure 8A). None of the peptides induced any
significant permeabilization of the E. coli inner membrane other than L1-R at the highest
concentrations tested (Figure 8B).
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Figure 8. Membrane Permeabilization of E. coli. E. coli, A, outer membrane and, B,
inner membrane permeabilization. L1 is shown in light blue, L1-Q in orange, L1-K in
gray, L1-R in yellow, L1-O in dark blue, and L1-X in green. All data are averages of at
least three replicates and error bars represent the SD. In some cases, error bars are smaller
than the size of the symbols.
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Figure 9. E. coli Outer Membrane Permeabilization Assay. Absorbance at 486 nm
represents the breakdown of the nitrocefin substrate by the periplasmic enzyme β‐
lactamase. Bacteria were exposed to varying concentrations of peptide and the
corresponding colors for each panel are shown in the legend. (A) L1, (B) L1‐Q, (C) L1‐
K, (D) L1‐R, (E) L1‐O, (F) L1‐X, (G) Polymyxin B. Data represent the average and
SD of 3‐6 samples.
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Figure 10. E. coli Inner Membrane Permeabilization Assay. Absorbance at 420 nm
represents the breakdown of the ONPG substrate by the periplasmic enzyme β‐
galactosidase. Bacteria were exposed to varying concentrations of peptide and the
corresponding colors for each panel are shown in the legend. (A) L1, (B) L1‐Q, (C) L1‐
K, (D) L1‐R, (E) L1‐O, (F) L1‐X, (G) cetyltrimethylammonium bromide (CTAB).
Data represent the average and SD of 3‐6 samples.
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Although bacterial membrane permeabilization may be linked to antimicrobial
activity; the L1 peptides have been shown to also permeabilize mammalian membranes.
It is critical to understand if L1 peptides can kill host cells, which is why a hemolysis
assay was performed. The ability to disrupt human RBC membranes was investigated
using a hemolysis assay monitoring the release of hemoglobin after exposure to the
peptides for 1 hour. Percent leakage was calculated based on a subsequent treatment of
the RBCs with the bilayer disrupting detergent Triton X-100. The results are shown in
Figure 11, with none of the L1 peptides inducing any significant disruption of RBCs,
consistent with the previously published results on the related L2 peptide [99].

Figure 11. Hemolysis of Human Red Blood Cells (RBCs). Hemolysis of RBCs. Data
were normalized based on untreated RBCs (0% hemolysis) and RBCs treated with the
detergent Triton X-100 (100% hemolysis). L1 is shown in light blue, L1-Q in orange, L1K in gray, L1-R in yellow, L1-O in dark blue, and L1-X in green. All data are averages of
at least three replicates and error bars represent the SD. In some cases, error bars are
smaller than the size of the symbols.
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Peptide secondary structure. The changes in amino acid sequence can
inherently impact the structure that the peptides adopt in solution or when bound to
membranes. Due to their small size, the L1 peptides are unlikely to adopt any tertiary
structures, so secondary structure analysis by CD spectroscopy provides a good picture of
the overall peptide structure. CD spectra of the L1 peptides in phosphate buffer alone or
in buffer with 3:1 PC:PG vesicles are shown in Figure 12. In aqueous solution, all
peptides exhibit CD spectra consistent with random / disordered structures except L1-O
which exhibits a helical signature. When bound to lipid vesicles, all variants exhibited
spectra indicative of α-helix formation.
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Figure 12. Circular Dichroism (CD) Spectroscopy. Spectra of all peptides were collected
in, A, 10X diluted PBS, B, 50:50 PBS:TFE using the 10X diluted PBS, C, in the presence
of 250 μM 3:1 PC:PG vesicles, or, D, in the presence of 250 μM 3:1 PC:Cholesterol
vesicles. In 10X diluted PBS and 50:50 PBS:TFE, the peptide concentration was 5 μM,
while in the presence of lipid vesicles, the peptide concentration was 3 μM. L1 is shown
in light blue, L1-Q in orange, L1-K in gray, L1-R in yellow, L1-O in dark blue, and L1-X
in green. All data represent the average of 64 scans with correction of background spectra
lacking peptide.

Discussion
When analyzing the data, it is important to remember that the L1 peptide is
derived from venom of an omnivorous species of ant which forages for both plants and
insects as food [138]. Thus, the primary function of the venom peptides is not evolved for
antimicrobial activity, but instead for offensive or defensive purposes. Additionally,
venoms often contain multiple components which can act synergistically or act on
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different and unrelated targets [139-141]. This can be further complicated by variations in
the diet and habitat of the insect as well as the season [142].

Net charge. One of the goals of the current study was to investigate the role of
net charge on AMP properties. Although the majority of AMPs that have been studied
have a net positive charge, many, including L1, have anionic amino acids in the
sequence. If net positive charge is a driving force for antimicrobial activity,
evolutionarily there would be no selective pressure to retain these anionic amino acids in
the sequence. However, this evolutionary pressure is not as clear in venom peptides,
which can also act as antimicrobials.
In solution, the change of net charge from +5 to +6 or +7 did not have a
significant impact on the REES results but were dramatically different for TCE
quenching profiles. As the REES and TCE assays report on different aspects of Trp
behavior (mobility and accessibility, respectively), the differences are potentially rooted
in structural or aggregation state changes in the peptide in solution. [130-131, 143]
The CD spectra in Figure 11 indicate these three peptides (L1, L1-Q, L1-K) are
not helical when in solution alone. However, the amino acid substitutions to change the
net charge of the peptide are all at position 4, while the native Trp is at position 6 (Figure
1). These substitutions inherently likely do not impact the rotational freedom of the Trp,
but may impact the local environment regarding polarity and/or the local packing of any
aggregated form. Previous studies have shown that local interaction between anionic
residues and Trp can impact spectral position and shifts [144-145], as well as peptidepeptide interactions [146-148].
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The effect of increasing L1 net charge had marked effects on the antimicrobial
efficacy against S. aureus and P. aeruginosa (Table 1). Increasing the charge from +5 to
+6 resulted in an eightfold enhancement of activity against S. aureus and a twofold
enhancement against P. aeruginosa while further increase of net charge to +7 further
twofold increased the efficacy against P. aeruginosa. Notably, these changes also
enhanced activity against E. coli and A. baumannii, but the parent L1 was already quite
effective against those strains. This is consistent with previous reports that demonstrate
cationic charge and net charge are important determinants of antimicrobial activity in
AMPs [143, 149-151]. These changes, however, do not appear to be driven by increased
ability to permeabilize vesicles or native membranes. While increasing the net charge did
result in moderate enhancements to lipid binding, this enhancement was not dependent on
bilayer charge. These results may point to a nonpermeabilizing role of L1 peptides in
antimicrobial activity.
Additionally, altering the net charge on the peptide can alter the
hydrophobic/hydrophilic balance of the sequence. Numerous studies on AMPs and
peptidomimetic polymers have shown that this balance plays a key role in antimicrobial
activity, cytotoxicity, and interactions with lipid bilayers [152-153]. In the peptides
presented here, the overall hydrophobic balance is not significantly impacted as E to Q to
K changes at position 4 are all polar. Notably, Gln is an uncharged polar residue which is
naturally less polar than Lys, but does not result in major differences in lipid bilayer
binding or antimicrobial activity. As such, any small changes in the
hydrophobic/hydrophilic balance, if at all, are swamped by the change in net charge.

45

Cationic side chain identity. While the net charge of the peptide does appear to
play some role in activity and may have strain-specific influences, previous studies on
peptides and peptidomimetic polymers have shown that not all cationic groups behave
identically in AMPs. Side chain length and cationic moiety identity have both been
shown to dramatically impact characteristics of antimicrobials [154-157]. Additionally,
the well-studied TAT sequence, originally derived from HIV, has shown a necessity for
Arg residues to function in membrane translocation [158-159]. In the L1 background,
switching Lys to Arg had minimal effects on MIC and MBC for all strains tested, except
P. aeruginosa which had a marked decrease in efficacy. Interestingly, the Lys to Arg
substitution resulted in a twofold decrease in MIC (increased efficacy) against E. coli,
consistent with several Trp-rich sequences described by Arias et al. A number of studies
have shown that Arg substitutions for Lys would enhance antimicrobial activity [160161], likely from an increased H-bonding network and ability to interact with more lipid
molecules for each cationic moiety [162].
Side chain length also clearly plays a role in activity and characteristics of the L1
peptides. Reducing the side chain length by one methyl group (Lys to Orn) had little
effect on efficacy or binding, but reduction by three methyl groups (Lys to Dap)
dramatically increased the MIC values. This is consistent with previous results on AMPs
and peptidomimetic polymers. However, a recent report by Hodges and coworkers has
shown the inclusion of Dap in AMPs can cause a small reduction of antibacterial activity
but can have a significant reduction in hemolytic activity, improving the overall
therapeutic potential [163]. The loss of activity from shortening the length of the cationic
side chain has been attributed to peptide penetration depth in the bilayer, the Dap side
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chain forcing a shallower, less disruptive conformation. The DQA results indicate that the
L1-X does appear to adopt a shallower orientation in PE:PG membranes (model of
bacterial membranes) but shows less of a difference compared to the L1-K in PC or
PC:PG membranes. This is consistent with the best performing sequences against E. coli
also exhibiting the greatest OM disruption and lowest Q-ratio in PE:PG membranes.
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Chapter 3
Synergistic Interactions of Ionic Liquids and Antimicrobials to Improve Efficacy
Introduction
Physiochemical properties of ionic liquids. Ionic liquids (ILs) are classified as
novel organic salts, that exist in liquid form at room temperature [164-165]. ILs are
composed of large organic cations or anions with alkyl chain substituents that can alter
the hydrophobicity of the molecule. Common cations found in ILs include imidazolium
or pyridinium, while anions include hexafluorophosphate, tetrafluoroborate, chloride,
nitrate, and bromide [166]. ILs have been studied for a variety of applications such as
electrochemical, industrial, and biomedical. Although there are many studies focusing on
electrochemical applications, potential applications include drug delivery, enzymatic
reaction enhancement, and use as biomaterials. ILs are advantageous due to their unique
physiochemical properties such as low melting points, exceptional solvation potential,
low volatility, and negligible vapor pressure [82]. These properties are able to be
manipulated easily by altering their ions, alkyl chain length, or type of head group [167168]. Long-chain imidazolium based ILs exhibit an amphiphilic conformation with a
charged hydrophilic head group and hydrophobic tail [169]. When in aqueous solution,
ILs exhibit a rod-like micelle formation [170-171].

Ionic liquids as antimicrobials. Studies have shown prominent antibacterial activity
of imidazolium ILs against bacteria and fungi due to their surfactant-like properties [172173]. However, the antimicrobial activity of each IL is dependent on the length of the
alkyl chain. A study performed by Cook et al., had shown as the alkyl chain increased, so
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did the antimicrobial activity. The imidazolium salts with 8 carbon atoms in the chain
exhibited activity against a broad spectrum of both Gram-positive and Gram-negative
bacteria. Their results concluded that antimicrobial activities correlate to ILs
hydrophobicities (increasing alkyl chain length). However, while ILs have been shown to
exhibit antimicrobial activity and the mechanism of action has begun to be explored,
several key challenges must be overcome to identify whether ILs have potential as
therapeutic agents.
A promising method for use of ILs as antimicrobials, is to enhance efficacy of
existing antimicrobials in combination with ILs. This study combines imidazolium
chloride based ILs with differing alkyl tails in combination with various commercially
available antimicrobials to examine the potential synergistic antimicrobial effects on
various bacteria, along with human cells to determine cytotoxic limits.

Materials and Methods
Ionic liquid preparation. Ionic liquids used in this study: 1-ethyl-3methylimidazolium chloride, [EMIM]Cl, Sigma; 1-butyl-3-methylimidazolium chloride,
[BMIM]Cl, Sigma; 1-hexyl-3-methylimidazolium chloride, [HMIM]Cl, Alfa Aesar; and
1-octyl-3-methylimidazolium chloride, [OMIM]Cl, Alfa Aesar; ([DMIM]Cl). Solutions
of IL at indicated concentration created with either PBS (Phosphate Buffer System) or
water solvent as indicated by experiment.

Critical micelle concentration (CMC) with tetracycline. Stocks of 2 mM
sodium phosphate buffer, 10 ug/mL Tetracycline, and 1.0 M [OMI]Cl, and [DMI]Cl were
prepared. DPH concentration was determined by absorbance spectroscopy using ε350 =
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88,000 [174]. In a black, clear flat bottom 96-well plate, 50 µL of serially diluted IL was
placed in each well. Then, calculated amount of buffer was added to each well. Once all
wells contained buffer and IL, correct amount of tetracycline for final concentrations of 1
µg/mL, 0.1 µg/mL, 0.01 µg/mL, or 0 µg/mL was added to the wells. Right before
measurement, DPH (final concentration 2.5µM) was added with gentle mixing by
pipetting to ensure no bubbles were formed. Samples were measured using λex = 358 nm
and λem = 430 nm.

Bacterial culturing. Bacteria were streaked on LB-Miller agar plates from a
frozen glycerol stock (-80°C) (Escherichia coli D31 [124], Staphylococcus aureus ATCC
35556, Pseudomonas aeruginosa PA-01 [175], Acinetobacter baumannii ATCC 19606,

Klebsiella pneumoniae ATCC 700603, Bacillus subtilis ATCC:6051). An overnight was
prepared using a single colony of each bacterial strain into fresh LB broth and placed into
a shaking incubator 37°C at 225 rpm for ~18 hours. After incubating overnight, a fresh
1:200 dilution was made in LB broth and used for the experiment.

Minimal Inhibitory Concentration (MIC). Same procedure performed as
described in Chapter 2.

Results
Previous work has demonstrated antimicrobial effects of ILs and a strong
correlation between increased alkyl-chain length and minimal inhibitory concentration
(MIC) [91, 176]. In this study we evaluated both the magnitude of this antimicrobial
effect as well the potential mechanism of actions for 3-methylimidazolium chloride ILs
of differing in alkyl chain length (Figure 13).
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Figure 13. Imidazolium Chloride Ionic Liquids with Various Alkyl Chain Lengths

Critical Micelle Concentrations (CMCs) with tetracycline. A possible mechanism
for antimicrobial effects of ILs include the ability of the IL to act as a detergent and
destabilize the cell membrane. An alternative hypothesis is that the amphipathic nature of
ILs may directly impact an associated antimicrobial compound through the formation of
micelles. Micelles are roughly spherical structures formed by amphiphilic molecules in
which the nonpolar portion of the molecule is buried at the interior of the structure while
the polar portions are exposed, favorably interacting with the aqueous environment.
Previous work has shown that some imidazolium ILs can form micelles and thus if
antimicrobials affect the CMC, it would inherently impact the antimicrobial activity
[177]. Using a fluorescence-based assay with the environmentally sensitive fluorophore
DPH, CMC of [OMIM]Cl and [DMIM]Cl was measured in the absence or presence of
various concentrations of tetracycline (Figure 14). In this assay, DPH fluorescence
intensity increases dramatically upon formation of micelles due to DPH partitioning into
the nonpolar core of the micelle [174]. The data shows that tetracycline has minimal
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effect on the formation of micelles over a 100-fold concentration range tested compared
to the no tetracycline control for both ILs examined. Thus, any effects of tetracycline in
combination with ILs are likely due to true synergistic behavior rather than influence on
micellar properties.

Figure 14. Critical Micelle Concentration (CMC) with Tetracycline. Imidazolium
chloride ILs with various alkyl chain lengths tested in combination with tetracycline

Minimum Inhibitory Concentration (MIC). Microbial inhibition effects were
evaluated using 3-methylimidazolium chloride ILs of differing in alkyl chain length with
six microbial strains (S. aureus, B. subtilis, P. aeruginosa, K. pneumoniae, E. coli, S.

aureus, and A. baumanii). In agreement with other studies, baseline MIC experiments
suggest that alkyl chain lengths of 6, 8, and 10 exhibit independent antimicrobial effects
with longer chain lengths exhibiting the greatest inhibition across a variety of
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microorganisms (Table 4). MIC values, there is a direct correlation between longer alkyl
chain lengths. For those ILs which presented with an antimicrobial effect, [HMIM]Cl,
[OMIM]Cl, and [DMIM]Cl demonstrated a direct correlation between IL concentration,
and ability to inhibit bacterial growth.

Table 4

MIC (mM) of ILs

Note. MIC, Minimum Inhibitory Concentration

Discussion
Amphiphilic molecules, such as ILs, can act as antimicrobials by interacting with
the bacterial membrane in a detergent like manner causing destabilization of the
membrane [178]. The activity of these molecules is linked to the monomer-micelle
equilibrium, which dramatically changes the physical and chemical properties of the
molecules. Several lines of experiments point to the ability of imidazolium chloridebased ILs to permeabilize cell membranes. Previous work has shown that some of these
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imidazolium ILs can form micelles and thus if tetracycline affects the CMC, it could
inherently impact the antimicrobial activity [177]. Micelle formation is primarily
governed by concentration, and the concentration at which micelles form is known as the
Critical Micelle Concentration (CMC). CMC has been shown to be influenced by salt
concentration and other additives in solution [179]. Our results point to the fact that
tetracycline does not significantly affect the ability of [OMIM]Cl or [DMIM]Cl to form
micelles (Figure 14). One possible interpretation of this finding is that tetracycline does
not enhance the detergent-like properties of ILs action on the cellular membrane, but
rather the addition of [OMIM]Cl or [DMIM]Cl to microbial populations acts
independently of antimicrobial compound to elicit a membrane destabilizing effects to
enhance the efficacy of the antimicrobial compound applied.
Other experiments were performed to determine synergistic effects of
imidazolium chloride based ILs and broad spectrum of commercially available
antibiotics, along with testing human cyctotoxicity (data not shown). These tests
consisted of a permeability assay using flow cytometry, bactericidal disc assay (zone of
inhibition assay), and treatment of HeLa cells in the presence of ILs and tetracycline.
When combining imidazolium chloride based ILs with an alkyl chain of 6 and 8,
synergistic interactions with a wide-range of antimicrobials was shown. Two separate
complementary assays were performed, a 96-well liquid culture and a zone of inhibition
(ZOI) disc assay. The results (data not shown) exhibited that when ILs ([HMIM]Cl and
[OMIM]Cl) and commercial antimicrobials (tetracycline (12.5 mg/mL), doxycycline
hyclate (10 mg/mL), and clindamycin (5 mg/mL)) were used in combination, the
necessary concentration of antimicrobial compound to inhibit growth was reduced.
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Interestingly, while a surprisingly large number of different antimicrobials were
enhanced by the addition of IL, many trends point to specific modes of action for synergy
of IL and antimicrobials. One of the strongest examples of synergism, that was evident in
various assays, was shown with addition of IL and tetracycline. The efficacy of
doxycycline was also strongly enhanced in the ZOI experiments along with the
antimicrobial clindamycin. These three antibiotics are in the tetracycline family, an
antibiotic class that inhibits protein synthesis by targeting the 30S ribosomal subunit
[184]. It has been suggested that the limited efficacy of tetracycline, as well as the
mechanism for antibiotic resistance, revolves around limited uptake and retention by
bacterial strains [185]. Given the potential membrane destabilizing effect of long-alkyl
chain ILs, it is reasonable to hypothesize that the addition of IL enhances the ability of
this class of antibiotics to enter and maintain higher concentrations within the bacterial
cell.
Although ILs are known as biocompatible, non-toxic, and a green alternative, this
classification is only realistically applied in limited concentrations. Recent reports
highlight the toxicity of this class of molecules [186]. To examine the imidazolium based
chloride ILs of varying alkyl chain length potential toxicity to mammalian cells, a
combinatorial treatment of ILs and tetracycline was applied to mammalian cells. Through
a limited approximation, the HeLa human cell line assays are the first step in identifying
the potential human response to the combinatorial treatment of ILs and antibiotics [187].
When exposing human cell lines to high concentrations of ILs, toxicity is exhibited.
However, HeLa cells treated with longer alkyl chain lengths, [OMIM]Cl, are less viable
than when treated with [HMIM]Cl at the same final concentration. The results indicated
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that when combining [HMIM]Cl and tetracycline, a clear synergistic response was shown
in the reduced amount of tetracycline required to reach 70% lethality in P. aeruginosa,
and the addition of [HMIM]Cl to HeLa cells did not increase the toxicity of tetracycline
in culture. This suggests that the combination of imidazolium chloride based ILs with
antimicrobials is able to reduce the amount of antibiotic necessary to combat bacterial
growth while having little to no additional toxic effect in human cell lines.
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Chapter 4
Conclusions
Ponericin L1 Data
The data shows that the L1 peptide is a membrane-binding peptide that can adopt
an α-helical conformation when bound to lipid bilayers. Both the net charge and the
identity of the cationic groups on the peptide play a significant role in antimicrobial
activity. As net charge increased from +5 to +7 the antimicrobial activity also increased.
The shortened cationic side chains decreased the antimicrobial activity. Decreased
antimicrobial activity in the shortened cationic side chains may be due to the peptide not
being able to interact with the lipid bilayer as deeply as the longer side chains. The
peptides adopted different conformations in zwitterionic and anionic vesicles which
somewhat correlate to the antimicrobial activity. However, the E. coli OM disruption
correlated best with MIC. The venom peptide L1 has good potential as a selective
antimicrobial platform due to tunable activity and low hemolytic activity. Future studies
on the hydrophobic/hydrophilic balance and the role of the polar face of the peptide
should provide important fundamental understanding and will help in designing a more
effective and selective antimicrobial molecule.

Antimicrobial Activity of Ionic Liquids Data
The data shows that there is an unknown synergistic interaction between
imidazolium chloride based ILs and a broad class of antimicrobials against bacteria. Our
results suggest that the combination of imidazolium chloride-based ILs with
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antimicrobials is capable of reducing the amount of antibiotic necessary to combat
bacterial growth while having little to no additional toxic effect in human cell lines. The
mechanism of action for why the apparent enhancement of antibiotic delivery is effective
in microbial cell populations but not mammalian cells is still unknown. One potential
biochemical explanation is that antibiotic action is regulated by internal cellular
concentration and that at typical treatment concentrations microbes have a baseline
ability to exclude or remove antibiotics. Overall, the addition of ILs can enhance the
delivery and/or retention of antimicrobials to both microbes and mammalian cells but due
to the lack of specificity of antimicrobial targets in mammalian cells, the toxicity of the
antimicrobial is not increased. Future investigations will need to be performed to assess
the underlying mechanism that protects the mammalian cells from higher concentrations
of antibiotics while simultaneously eliciting a synergistic response in improving the
efficacy of antimicrobial compounds for combating bacterial growth.
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